Log in to save to my catalogue

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inh...

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inh...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1989590339

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

About this item

Full title

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2018-02, Vol.24 (2), p.203-212

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Expression of AXL earmarks melanoma cells resistant to BRAF and MEK inhibitors that either pre-exist in treatment-naive tumors or emerge in response to therapy. The combination of an AXL-MMAE antibody-drug conjugate with BRAF and MEK inhibitors eliminates heterogeneous melanoma cell populations and prolongs survival in experimental
in vivo
mo...

Alternative Titles

Full title

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1989590339

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1989590339

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/nm.4472

How to access this item